Trial · NCT05378646
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
NCT05378646, Phase 3, Completed, SPP Pharmaclon Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis. Trials, record NCT05378646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05378646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
- NCT number
- NCT05378646
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 30 participants, actual
- Lead sponsor
- SPP Pharmaclon Ltd.
- Conditions
- Chronic Prostatitis
- Interventions
- Interferon gamma human recombinant (IFN-G)
- First posted
- 2022-05-18
- Last updated
- 2022-05-18
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dynamics of the total score and improvement in the quality of life on the scale IPSS. | Day 13 | The sum of points was assessed, as well as the symptom complex on the basis of the "IPSS" questionnaire - the international system for the total assessment of symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms was assessed from 0 to 6 points. symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms is rated from 0 to 6 points. |
| Primary | Immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 14 | Content of polymorphonuclear leukocytes in prostate secretion. |
| Primary | Immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 14 | The content of lymphocytes in prostate secretion. |
| Primary | Evaluation of cytological parameters of prostate secretion. | Day 14 | The number of lecithin grains. |
| Primary | Evaluation of cytological parameters of prostate secretion. | Day 14 | The number of epithelial cells. |
| Primary | Microscopy of prostate secretion and immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 14 | The effect of interferon-gamma on T-lymphocytes. |
| Primary | Evaluation of cytological parameters of prostate secretion. | Day 90 | The content of polymorphonuclear leukocytes in prostate secretion. |
| Primary | Immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 90 | The content of lymphocytes in prostate secretion. |
| Primary | Evaluation of cytological parameters of prostate secretion. | Day 90 | The number of lecithin grains. |
| Primary | Evaluation of cytological parameters of prostate secretion. | Day 90 | The number of epithelial cells. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05378646
GET https://conductscience.org/api/trials/v1/NCT05378646/registered